TrialMedicine2017

A randomized, multicenter, phase III study of gemcitabine combined with capecitabine versus gemcitabine alone as first-line chemotherapy for advanced pancreatic cancer in South Korea.

Hee Seung Lee et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.